-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DJwIf18qpXpe72HQMmPYDNHsZMTNIky1et5VeGGeCXFySLPElhO+lYpK9ccuLTpM wlJ74/QTfo/0sFnnWMNRig== 0000912057-02-039394.txt : 20021022 0000912057-02-039394.hdr.sgml : 20021022 20021022160052 ACCESSION NUMBER: 0000912057-02-039394 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20021022 EFFECTIVENESS DATE: 20021022 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VISIBLE GENETICS INC CENTRAL INDEX KEY: 0001010819 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-28550 FILM NUMBER: 02795129 BUSINESS ADDRESS: STREET 1: 700 BAY ST STREET 2: SUITE 1000 CITY: TORONTO ONTARIO CANA STATE: A6 ZIP: 00000 BUSINESS PHONE: 2127025700 MAIL ADDRESS: STREET 1: 700 BAY ST STE 1000 STREET 2: TORONTO ONTARIO CANADA CITY: M5G 1Z6 15-12G 1 a2091213z15-12g.txt FORM 15-12G AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 22, 2002 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. COMMISSION FILE NUMBER 0-28550 Visible Genetics Inc. - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) 700 Bay Street, Suite 1000 Toronto, Ontario M5G 1Z6 (416) 813-3240 - -------------------------------------------------------------------------------- (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Common Shares - -------------------------------------------------------------------------------- (Title of each class of securities covered by this Form) - -------------------------------------------------------------------------------- (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains) Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports: Rule 12g-4(a)(1)(i) |_| Rule 12h-3(b)(1)(i) |_| Rule 12g-4(a)(1)(ii) |_| Rule 12h-3(b)(1)(ii) |_| Rule 12g-4(a)(2)(i) |X| Rule 12h-3(b)(2)(i) |X| Rule 12g-4(a)(2)(ii) |_| Rule 12h-3(b)(2)(ii) |_| Rule 15d-6 |_| Approximate number of holders of record as of the certification or notice date: One (1)* * On October 11, 2002, Bayer Corporation, an Indiana corporation ("Bayer Corp."), 2014011 Ontario Inc., an Ontario corporation and wholly-owned subsidiary of Bayer Corp. ("AcquireCo"), and Visible Genetics Inc., an Ontario corporation ("VGI") consummated a transaction whereby AcquireCo acquired all of the outstanding common shares of VGI and all of the outstanding Series A Convertible Preferred Shares of VGI and amalgamated with VGI to form an amalgamated company ("Amalco"), which retained the corporate name Visible Genetics Inc., under the Business Corporations Act (Ontario) (the "Transaction"). As a result of the Transaction, Bayer Corp. owns all of the outstanding common shares of Amalco and Amalco is the successor by amalgamation to VGI. No other shares of capital stock of Amalco are outstanding. Pursuant to the requirements of the Securities Exchange Act of 1934, Visible Genetics Inc., as successor by amalgamation, has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person. Date: October 22, 2002 VISIBLE GENETICS INC. /s/ Peter C. Knueppel --------------------------- By: Peter C. Knueppel Title: President -----END PRIVACY-ENHANCED MESSAGE-----